The combination of lenvatinib and pembrolizumab is FDA-approved for patients with advanced renal cell carcinoma (#RCC). In a recent study, investigators sought to assess its efficacy and safety in patients with locally advanced, non-metastatic clear cell RCC. Overall, the combination showed promising clinical activity and an acceptable safety profile in this patient population. According to lead author Mehmet A. Bilen, MD, of Winship Cancer Institute of Emory University, these findings warrant further investigation. 🔗 Read the full interview here: https://lnkd.in/eBtiTkYB
